Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
-
Abiraterone is an inhibitor of androgen biosynthesis indicated for the treatment of metastatic castration-resistant prostate cancer. Common side effects include diarrhea, edema, hypokalemia, hypertension, and liver function test abnormalities. We report a case of rhabdomyolysis developing in association with the use of abiraterone. Following discontinuation of abiraterone, creatine kinase concentrations decreased gradually throughout the duration of the hospitalization.